Vaxart Competitors, Revenue, Alternatives and Pricing
Overview
Industry Ranking
Estimated Revenue & Financials
- Vaxart's estimated annual revenue is currently $4.2M per year.
- Vaxart received $18.4M in venture funding in January 2015.
- Vaxart's estimated revenue per employee is $122,324
- Vaxart's total funding is $58.6M.
Employee Data
- Vaxart has 34 Employees.
- Vaxart grew their employee count by -17% last year.
- Vaxart currently has 1 job openings.
Vaxart Competitors & Alternatives
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Online Review | Pricing |
|---|---|---|---|---|---|---|
| Advertise Here | ||||||
#1 | $7M | 45 | 10% | N/A | - | N/A |
#2 | N/A | 205 | N/A | N/A | - | N/A |
#3 | $46.8M | 302 | 4% | N/A | - | N/A |
#4 | $22.3M | 144 | N/A | N/A | - | N/A |
#5 | $44.3M | 286 | N/A | N/A | - | N/A |
#6 | $101.2M | 653 | 46% | N/A | - | N/A |
#7 | $18.6M | 120 | N/A | N/A | - | N/A |
#8 | $23.3M | 150 | N/A | N/A | - | N/A |
#9 | $33.3M | 215 | 3% | N/A | - | N/A |
#10 | $28.7M | 185 | 8% | N/A | - | N/A |
What Is Vaxart?
Vaxart is a clinical-stage company developing tablet vaccines based on its proprietary oral vaccine platform. The lead programs are prophylactic oral vaccines for seasonal influenza, RSV and norovirus, as well as a therapeutic vaccine for HPV types 16 and 18. Vaxart vaccines are convenient room temperature-stable tablets that are easy to administer, and that eliminate risk of needle-stick injury and medical waste associated with injectable vaccines. The company is listed on the NASDAQ exchange under ticker nymbol VXRT.
keywords:Biotechnology,Healthcare,Pharmaceuticals34
Number of Employees
$4.2M
Revenue (est)
1
Current Jobs
-17%
Employee Growth %
$58.6M
Total Funding
N/A
Valuation
N/A
Accelerator
B2B
Type
Vaxart News
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--. Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant ...
Stock analysts at Brookline Capital Management assumed coverage on shares of Vaxart (NASDAQ:VXRT) in a research note issued on ...
Vaxart (NASDAQ:VXRT) has been given a $2.00 target price by HC Wainwright in a research note issued on Wednesday, August 21st, ...
Other Companies in South San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding | Online Review | Pricing |
|---|---|---|---|---|---|---|
#1 | $5.3M | 34 | 55% | N/A | - | N/A |
#2 | $7.2M | 35 | N/A | N/A | - | N/A |
#3 | $5.4M | 35 | 52% | N/A | - | N/A |
#4 | $6.2M | 40 | 54% | N/A | - | N/A |
#5 | $6.2M | 40 | 82% | N/A | - | N/A |
Vaxart Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2007-11-16 | $3.3M | A | Quantum Technology Partners, Life Science Angels | Article |
| 2010-03-05 | $12.5M | B | Care Capital of Princeton NJ | Article |
| 2013-08-07 | $20.0M | C | Article | |
| 2015-01-09 | $18.4M | Undisclosed | Care Capital | Article |
Vaxart Executive Hires
| Date | Name | Title | Reference |
|---|---|---|---|
| 2014-05-09 | John M. Harland | CFO | Article |
| 2016-02-10 | Samir Singh | SVP corporate development and strategy. | Article |
| 2018-04-20 | Brant Biehn | SVP Commercial Operations | Article |
| 2018-05-02 | David Taylor | Chief Medical Officer | Article |
Vaxart Acquisitions
| Date | Company Name | Amount | Notes | Reference |
|---|---|---|---|---|
| 2018-02-01 | Aviragen Therapeutics | Article | ||
| 2018-02-14 | Aviragen Therapeutics | Article |